SubsidieMeestersImmune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours
Padeliporfin-VTP therapy offers a minimally invasive treatment for UTUC by using laser-activated photosensitizers to eliminate tumors while preserving organ function, aiming for regulatory approval and market entry.
Projectdetails
Introduction
UTUC is a non-systemically treatable cancer that forms in the renal pelvis or ureter, frequently recurring due to ineffective systemic chemotherapy. With 5-10% of urothelial cancers being UTUC, current surgical treatment solutions pose significant hardships on patients and decrease their quality of life.
Proposed Solution
Our proprietary solution, Padeliporfin-VTP therapy, offers a minimally invasive and effective alternative to surgery. This therapy delivers an inactive photosensitizer drug that is precisely activated in the tumour micro-environment by non-thermal laser light, immediately impeding the tumour's blood supply, leading to cell death with minimal effect on healthy tissues.
Benefits of Treatment
This treatment not only effectively eliminates tumours, but also preserves organ functionality for potential future treatments.
Project Leadership
This project is led by a team of accomplished professionals in the pharmaceutical and biopharma industry, which solidifies our capability in innovating best-in-class therapeutic solutions.
Funding Utilization
Utilising this funding, we aim to achieve:
- Regulatory approval (TRL9)
- Scale production
- Achieve market penetration in a market projected to reach €4.39B by 2032.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.498.730 |
| Totale projectbegroting | € 2.498.730 |
Tijdlijn
| Startdatum | 1-12-2024 |
| Einddatum | 30-11-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- IMPACT BIOTECH LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes. | EIC Accelerator | € 2.306.500 | 2024 | Details |
Autonomous robotics and digital TWIN to improve water network performancesThe project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model. | EIC Accelerator | € 2.478.210 | 2024 | Details |
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming systemToopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability. | EIC Accelerator | € 2.396.457 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""
NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes.
Autonomous robotics and digital TWIN to improve water network performances
The project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model.
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming system
Toopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Innovative Photoactivated Ruthenium Chemotherapy to treat eye cancerPACT4EYE aims to develop a novel photoactivated chemotherapy using a ruthenium prodrug to treat uveal melanoma, enhancing patient outcomes by targeting tumors in hypoxic conditions. | EIC Transition | € 2.499.998 | 2023 | Details |
Specific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELiminationSCALPEL aims to revolutionize cancer treatment by using photodynamic therapy to destroy tumors while marking surviving cells for immune system targeting, potentially offering a curative photoimmunotherapy. | EIC Pathfinder | € 4.554.301 | 2025 | Details |
Chemogels voor de behandeling van uitgezaaide buikvlieskankerUPyTher BV ontwikkelt innovatieve hydrogelformuleringen voor intraperitoneale therapieën om de behandeling van buikvlieskanker te verbeteren en onderzoekt de technische en commerciële haalbaarheid ervan. | MIT Haalbaarheid | € 20.000 | 2023 | Details |
PRO CellecTPan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren. | MIT Haalbaarheid | € 20.000 | 2021 | Details |
Innovative Photoactivated Ruthenium Chemotherapy to treat eye cancer
PACT4EYE aims to develop a novel photoactivated chemotherapy using a ruthenium prodrug to treat uveal melanoma, enhancing patient outcomes by targeting tumors in hypoxic conditions.
Specific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELimination
SCALPEL aims to revolutionize cancer treatment by using photodynamic therapy to destroy tumors while marking surviving cells for immune system targeting, potentially offering a curative photoimmunotherapy.
Chemogels voor de behandeling van uitgezaaide buikvlieskanker
UPyTher BV ontwikkelt innovatieve hydrogelformuleringen voor intraperitoneale therapieën om de behandeling van buikvlieskanker te verbeteren en onderzoekt de technische en commerciële haalbaarheid ervan.
PRO CellecT
Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.